Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

5.950 -0.040 (-0.67%)
Streaming Delayed Price Updated: 10:42 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Agenus Inc

< Previous 1 2 3 Next >
AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm
From Schall Law Firm
Via Business Wire
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
From Agenus Inc.
Via Business Wire
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
From Agenus Inc.
Via Business Wire
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
From Agenus Inc.
Via Business Wire
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
From Agenus Inc.
Via Business Wire
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
From Agenus
Via Business Wire
Agenus Announces Virtual Annual Shareholders Meeting
From Agenus Inc.
Via Business Wire
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
From Agenus Inc.
Via Business Wire
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
From Agenus Inc.
Via Business Wire
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
From Agenus Inc.
Via Business Wire
Agenus Reports First Quarter 2024 Results
From Agenus Inc.
Via Business Wire
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Agenus Inc.
Via Business Wire
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
From Agenus Inc.
Via Business Wire
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
From Agenus Inc.
Via Business Wire
Agenus Announces Reverse Stock Split of Common Stock
From Agenus Inc.
Via Business Wire
Agenus Reports Fourth Quarter and Full Year 2023 Results
From Agenus Inc.
Via Business Wire
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
From Agenus Inc.
Via Business Wire
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
From Agenus Inc.
Via Business Wire
Agenus to Participate in Leerink Partners Global Biopharma Conference
From Agenus Inc.
Via Business Wire
Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Agenus Inc.
Via Business Wire
Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population
From Agenus Inc.
Via Business Wire
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Agenus to Participate in B. Riley Healthcare Conference
From Agenus Inc.
Via Business Wire
Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024
From Agenus Inc.
Via Business Wire
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
From Agenus Inc.
Via Business Wire
Agenus Reports Third Quarter 2023 Results
From Agenus Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.